Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks .

What is Agile Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for Agile Therapeutics' shares. Their AGRX share price targets range from $5.00 to $12.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 335.9% from the stock's current price. View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts .

How have AGRX shares performed in 2023?

Agile Therapeutics' stock was trading at $0.2270 at the beginning of 2023. Since then, AGRX stock has increased by 759.0% and is now trading at $1.95. View the best growth stocks for 2023 here .

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our AGRX earnings forecast .

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($1.47) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $6.66 million during the quarter.

When did Agile Therapeutics' stock split?

Shares of Agile Therapeutics reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics updated its FY 2023 earnings guidance on Thursday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $25.00M-, compared to the consensus revenue estimate of $21.66 million.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Nabriva Therapeutics (NBRV) , AcelRx Pharmaceuticals (ACRX) , Micron Technology (MU) and Novavax (NVAX) .

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Price, News & Analysis

$1.95

+0.03 (+1.56%)

(As of 12/29/2023 ET)

Compare

Today's Range: $1.85
▼
$1.97
50-Day Range: $1.75
▼
$2.47
52-Week Range: $1.65
▼
$16.00

Volume: 55,562 shs
Average Volume: 66,421 shs
Market Capitalization: $4.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Agile Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 335.9% Upside
$8.50 Price Target
Short Interest: Healthy
0.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.59
Upright™ Environmental Score
News Sentiment: 0.51
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Agile Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Agile Therapeutics has a forecasted upside of 335.9% from its current price of $1.95.
Amount of Analyst Coverage
Agile Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.35% of the float of Agile Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Agile Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Agile Therapeutics has recently increased by 23.88%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Agile Therapeutics does not currently pay a dividend.
Dividend Growth
Agile Therapeutics does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agile Therapeutics is -1.59.

2.5

News and Social Media Coverage

News Sentiment
Agile Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Agile Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agile Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.50% of the stock of Agile Therapeutics is held by insiders.
Percentage Held by Institutions
Only 7.52% of the stock of Agile Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Agile Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agile Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Agile Therapeutics Stock (NASDAQ:AGRX)

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AGRX Stock News Headlines

December 31, 2023 | americanbankingnews.com

Agile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest Up 23.9% in December

December 27, 2023 | americanbankingnews.com

Agile Therapeutics (NASDAQ:AGRX) Share Price Passes Above 50 Day Moving Average of $2.03

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.

December 12, 2023 | finance.yahoo.com

Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement

November 23, 2023 | msn.com

Agile Therapeutics reports Q3 results

November 21, 2023 | benzinga.com

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024

November 11, 2023 | markets.businessinsider.com

Agile Therapeutics: A Promising Investment with Positive Cash Flow Forecasts and Anticipated Growth in Twirla Sales

November 10, 2023 | finance.yahoo.com

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

November 9, 2023 | finance.yahoo.com

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023 | msn.com

Agile Therapeutics Q3 2023 Earnings Preview

October 26, 2023 | finance.yahoo.com

Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023

October 5, 2023 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

October 4, 2023 | finance.yahoo.com

Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2023 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Upgraded To "Buy" Rating By Analysts At Maxim Group

September 28, 2023 | finance.yahoo.com

Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group

September 27, 2023 | benzinga.com

Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group

September 5, 2023 | finance.yahoo.com

Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 17, 2023 | msn.com

Agile ($AGRX) Says It's On Track To Hit $25-$30M Net Annual Revenue After A Strong Performance In Q2

August 11, 2023 | finance.yahoo.com

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript

August 9, 2023 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023 | finance.yahoo.com

Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 26, 2023 | finance.yahoo.com

Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023

July 19, 2023 | finance.yahoo.com

This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys

July 18, 2023 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women

July 18, 2023 | msn.com

NASDAQ: $AGRX Biden's Executive Order Boosts Adoption Of Agile Therapeutics' Contraceptive Patch

July 14, 2023 | benzinga.com

Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women

See More Headlines

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AGRX
CUSIP: N/A
CIK: 1261249
Web: www.agiletherapeutics.com
Phone: (609) 683-1880
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $12.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +335.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($13.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,410,000.00
Net Margins: -69.73%
Pretax Margin: -69.73%
Return on Equity: N/A
Return on Assets: -188.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.57
Quick Ratio: 0.44

Sales & Book Value

Annual Sales: $10.88 million
Price / Sales: 0.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($6.83) per share
Price / Book: -0.29

Miscellaneous

Outstanding Shares: 2,510,000
Free Float: 2,499,000
Market Cap: $4.89 million
Optionable: Not Optionable
Beta: 1.85

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Alfred F. Altomari (Age 64)
Chairman, President & CEO
Comp: $644.4k
Mr. Geoffrey P. Gilmore (Age 57)
Senior VP & Chief Administrative Officer
Comp: $478.92k
Dr. Paul Korner M.B.A. (Age 57)
M.D., Senior VP & Chief Medical Officer
Comp: $480.4k
Mr. Scott M. Coiante (Age 56)
CFO, Senior VP & Treasurer
Comp: $520.45k
Matthew Riley
Head of Investor Relations & Corporate Communications
Mr. Robert G. Conway M.E. (Age 65)
Senior VP and Chief Corporate Planning & Supply Chain Officer
Comp: $444.11k
Ms. Amy Welsh (Age 52)
Senior VP & Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Sold 24,000 shares on 11/15/2023
Ownership: 5.078%

View All Institutional Transactions

AGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.
What is Agile Therapeutics' stock price target for 2024?: 2 Wall Street research analysts have issued 1-year target prices for Agile Therapeutics' shares. Their AGRX share price targets range from $5.00 to $12.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 335.9% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.
How have AGRX shares performed in 2023?: Agile Therapeutics' stock was trading at $0.2270 at the beginning of 2023. Since then, AGRX stock has increased by 759.0% and is now trading at $1.95.
View the best growth stocks for 2023 here.
When is Agile Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our AGRX earnings forecast.
How were Agile Therapeutics' earnings last quarter?: Agile Therapeutics, Inc. (NASDAQ:AGRX) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($1.47) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $6.66 million during the quarter.

When did Agile Therapeutics' stock split?: Shares of Agile Therapeutics reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What guidance has Agile Therapeutics issued on next quarter's earnings?: Agile Therapeutics updated its FY 2023 earnings guidance on Thursday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $25.00M-, compared to the consensus revenue estimate of $21.66 million.
What other stocks do shareholders of Agile Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).
How do I buy shares of Agile Therapeutics?: Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGRX) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial